ArticleBMC cancer2026
Obesity, survival, and chemotherapy outcomes in stage IV colorectal cancer: a retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fatigue 5 years after treatment for rectal cancer – results from the QoLiRECT studyActa oncologica (Stockholm, Sweden) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundObesity increases risk for colorectal cancer (CRC) development and historically has been connected to poor outcomes. The obesity paradox describes recent data showing that obesity may be protective in some diseases. This study examined the association between obesity and overall survival (OS) in stage IV CRC, evaluating factors that may contribute to disease course.
methodsThis was a single-institution, retrospective study of patients with stage IV CRC who underwent resection, chemotherapy, and/or radiation. Patients were grouped by body mass index (BMI) at diagnosis, as normal weight (NW), overweight, or obese. Cox regression models were used to estimate the effects of patient, disease, and treatment characteristics on OS.
results320 patients with stage IV CRC were identified, including 108 NW, 109 overweight, and 103 obese patients. No statistically significant differences were found in age, sex, race, primary tumor site, KRAS/BRAF mutational status, tumor stage, or treatment modality between groups. Obese patients more frequently had higher node-positive disease. Duration of chemotherapy significantly differed by BMI (median duration: NW = 6.5 months, overweight = 6.2, and obese = 11.7, p = 0.04). Chemotherapy adverse event scores and reasons for chemotherapy cessation did not differ by BMI group. On multivariable analysis, NW and overweight patients were at increased risk of death compared to obese patients (NW: HR 1.95, 95% CI 1.39–2.73; overweight: HR 1.43, 95% CI 1.03–1.99).
conclusionsObesity at diagnosis is associated with improved OS in stage IV CRC. Patients with obesity underwent a longer duration of chemotherapy and experienced greater decreases in BMI during this period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.